Psyence Biomedical Ltd (PBM)

$2.46 0.00 (N/A)
Market Cap 2.52M
Revenue (ttm) 0.00
Net Income (ttm) 1.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,100
Avg Vol 250,505
Day's Range N/A - N/A
Shares Out 1.02M
Stochastic %K 43%
Beta 0.36
Analysts Strong Buy
Price Target N/A

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 346 7764
Address:
121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada
Dman_22
Dman_22 Mar. 15 at 9:08 PM
$PBM the face that this thing is still below $10-$20 a share right now is mind blowing ?!?! Only a matter of time with all the positive results and good news coming out this year ! Just hold on people good times ahead I promise !😎👌
0 · Reply
erb71
erb71 Mar. 12 at 7:44 PM
$PBM It is intriguing that the market has yet to recognize the importance of this milestone. Perhaps it may have missed this news altogether, as implied by the minuscule volume. Anyway, it may be caught in time, as happens at many other biotech companies, where there are sometimes delays between news and market action. Let's see how it proceeds (not advice)
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 12 at 3:20 PM
$SPY psychedelics are great for PTSD $PBM
1 · Reply
Btolz
Btolz Mar. 11 at 4:33 PM
$PBM https://finance.yahoo.com/news/corporate-psyence-biomed-advances-vertically-131500448.html
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 11 at 3:43 PM
$PBM good news again, and no volume 🤨
0 · Reply
Jbjb90
Jbjb90 Mar. 11 at 1:19 PM
$PBM https://www.stocktitan.net/news/PBM/corporate-update-psyence-bio-med-advances-vertically-integrated-8uli53qnhvue.html
0 · Reply
StockNews_Live
StockNews_Live Mar. 11 at 1:15 PM
$PBM 🎯 STOCK NEWS ALERT 💵 Price: $2.47 (-1.57%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Psyence Biomedical Ltd. reinforced its strategic investment in PsyLabs, which strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure. Through this… 📎 https://stocknews.live/news/PBM/corporate-update-psyence-bio-64380.html
0 · Reply
Btolz
Btolz Mar. 11 at 1:02 PM
$PBM please come out with some positive news and make this thing jump
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 9 at 6:49 PM
$PBM it’s ready
0 · Reply
basicgirltrading
basicgirltrading Mar. 4 at 2:56 PM
$PBM who’s going to hit the ask? Only need like 100 @ 2.60, 100 @2.64 and 100 @ 2.65 for this to jump to 2.70 and hit scanners
0 · Reply
Latest News on PBM
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Mar 11, 2026, 9:15 AM EDT - 4 days ago

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Mar 3, 2026, 9:15 AM EST - 12 days ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Feb 20, 2026, 5:20 PM EST - 23 days ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Feb 17, 2026, 9:15 AM EST - 26 days ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Feb 13, 2026, 6:30 PM EST - 4 weeks ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Psyence BioMed Announces Settlement of Shareholder Litigation

Feb 11, 2026, 9:15 AM EST - 4 weeks ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 28, 2026, 6:30 PM EST - 6 weeks ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 22, 2026, 1:42 PM EST - 7 weeks ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 20, 2026, 7:19 AM EST - 7 weeks ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 12, 2026, 8:30 AM EST - 2 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Jan 5, 2026, 9:15 AM EST - 2 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 19, 2025, 7:00 AM EST - 3 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Dec 9, 2025, 7:00 AM EST - 3 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 25, 2025, 7:00 AM EST - 3 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 20, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 12, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 6, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Nov 3, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Aug 28, 2025, 8:00 AM EDT - 7 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 25, 2025, 5:00 PM EDT - 9 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 9 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 18, 2025, 8:30 AM EDT - 9 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Jun 17, 2025, 8:00 AM EDT - 9 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 27, 2025, 7:30 AM EDT - 10 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

May 1, 2025, 7:30 AM EDT - 11 months ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 7:17 PM EDT - 11 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Announces Share Consolidation

Apr 17, 2025, 9:39 AM EDT - 11 months ago

Psyence Group Announces Share Consolidation

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 15, 2025, 8:30 AM EDT - 11 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 14, 2024, 10:43 AM EDT - 1 year ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Oct 4, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Sep 20, 2024, 11:20 AM EDT - 1 year ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Dman_22
Dman_22 Mar. 15 at 9:08 PM
$PBM the face that this thing is still below $10-$20 a share right now is mind blowing ?!?! Only a matter of time with all the positive results and good news coming out this year ! Just hold on people good times ahead I promise !😎👌
0 · Reply
erb71
erb71 Mar. 12 at 7:44 PM
$PBM It is intriguing that the market has yet to recognize the importance of this milestone. Perhaps it may have missed this news altogether, as implied by the minuscule volume. Anyway, it may be caught in time, as happens at many other biotech companies, where there are sometimes delays between news and market action. Let's see how it proceeds (not advice)
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 12 at 3:20 PM
$SPY psychedelics are great for PTSD $PBM
1 · Reply
Btolz
Btolz Mar. 11 at 4:33 PM
$PBM https://finance.yahoo.com/news/corporate-psyence-biomed-advances-vertically-131500448.html
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 11 at 3:43 PM
$PBM good news again, and no volume 🤨
0 · Reply
Jbjb90
Jbjb90 Mar. 11 at 1:19 PM
$PBM https://www.stocktitan.net/news/PBM/corporate-update-psyence-bio-med-advances-vertically-integrated-8uli53qnhvue.html
0 · Reply
StockNews_Live
StockNews_Live Mar. 11 at 1:15 PM
$PBM 🎯 STOCK NEWS ALERT 💵 Price: $2.47 (-1.57%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Psyence Biomedical Ltd. reinforced its strategic investment in PsyLabs, which strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure. Through this… 📎 https://stocknews.live/news/PBM/corporate-update-psyence-bio-64380.html
0 · Reply
Btolz
Btolz Mar. 11 at 1:02 PM
$PBM please come out with some positive news and make this thing jump
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 9 at 6:49 PM
$PBM it’s ready
0 · Reply
basicgirltrading
basicgirltrading Mar. 4 at 2:56 PM
$PBM who’s going to hit the ask? Only need like 100 @ 2.60, 100 @2.64 and 100 @ 2.65 for this to jump to 2.70 and hit scanners
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 3 at 8:43 PM
$PBM 1 million shares. $5.4 million cash. Exporting psilocybin to Australia. Highly shorted. Hammer 🔨 on the daily. This one gonna 🏃‍♀️ soon!
1 · Reply
Jbjb90
Jbjb90 Mar. 3 at 6:21 PM
$PBM the whole market got walloped today, released good news on a bad day, its going up from here
0 · Reply
Btolz
Btolz Mar. 3 at 6:19 PM
$PBM we should see the volume increase as this news starts making its way across the web
0 · Reply
BioTuesdays
BioTuesdays Mar. 3 at 5:38 PM
$PBM has announced the export of fully GMP-compliant manufactured psilocybin product NPX-5 to Australia for the ongoing Phase 2b clinical trial evaluating natural psilocybin for the treatment of adjustment disorder in patients with cancer in a palliative care context. https://biotuesdays.com/2026/03/03/psyence-ships-gmp-compliant-psilocybin-to-australia-for-phase-2b-trial/
0 · Reply
Btolz
Btolz Mar. 3 at 3:27 PM
$PBM https://www.investing.com/news/assorted/psyence-biomed-exports-psilocybin-to-australia-for-phase-iib-trial-432SI-4538136
0 · Reply
Bikinibullshark
Bikinibullshark Mar. 3 at 2:48 PM
$PBM great news, no volume. Interesting 🤔
1 · Reply
Jbjb90
Jbjb90 Mar. 3 at 2:42 PM
$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-announces-export-of-gmp-manufactured-natural-vzf47b3b3llr.html
0 · Reply
StockNews_Live
StockNews_Live Mar. 3 at 2:15 PM
$PBM Psyence Biomedical Ltd. announced the successful export of fully GMP-compliant manufactured psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. The product was manufactured at the Psyence La…
0 · Reply
jadeite_haystack
jadeite_haystack Mar. 3 at 12:02 AM
$PBM 9.25
0 · Reply
Btolz
Btolz Mar. 2 at 9:37 PM
$PBM closed in the green lol
0 · Reply
REXOM
REXOM Mar. 1 at 4:33 PM
$OGEN $SOBR $PMEC $PBM $HCTI
0 · Reply
REXOM
REXOM Feb. 28 at 1:06 PM
5- We BANKED on my FREE DISCORD last week. the link is under my bio. My TOP calls for LAST WEEK part -5- were : 21- $OGEN 0.77 - 1.01 22- $SOBR 0.75 - 0.85 23- $PMEC 0.82 - 1.12 24- $PBM 3.10 - 3.60 25- $HCTI 8.80 - 11.65 If you do not want to miss these kind of calls, follow me on my FREE DISCORD.
0 · Reply